Kingswood Wealth Advisors LLC Has $1.34 Million Holdings in Pfizer Inc. $PFE

Kingswood Wealth Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 76.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,136 shares of the biopharmaceutical company's stock after selling 181,547 shares during the quarter. Kingswood Wealth Advisors LLC's holdings in Pfizer were worth $1,336,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter valued at approximately $27,000. North Capital Inc. bought a new stake in Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd bought a new stake in Pfizer in the first quarter valued at $28,000. Horizon Financial Services LLC bought a new stake in Pfizer in the first quarter valued at $35,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the first quarter valued at $35,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. UBS Group restated a "neutral" rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $28.41.

Pfizer Price Performance

Pfizer stock opened at $26.27 on Wednesday. The business's 50-day simple moving average is $24.76 and its 200 day simple moving average is $24.14. The stock has a market cap of $149.36 billion, a price-to-earnings ratio of 13.97, a P/E/G ratio of 0.86 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm posted $0.60 earnings per share. The company's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.